Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia
- Registration Number
- NCT03815812
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Brief Summary
IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and low-density lipoprotein cholesterol（LDL-C）uptake. In phase I study IBI306 was shown to be safe and well tolerated. There was robust reduction in LDL-C, Apo(B), non-HDL-C and lipoprotein (a) in healthy subjects. This study is a randomized, double-blind, placebo-controlled, repeated-dosing, multiple ascending dose trial to evaluate the safety and tolerability of a novel PCSK-9 anti-body, IBI306, in Chinese patients with hypercholesterolemia.
- Detailed Description
A total of 60 patients who meet the criteria for admission and have a clinical diagnosis of hypercholesterolemia and have received statin for at least 4 weeks will be randomized and receive different dose groups of IBI306 or matching placebo. Ascending dose design includes 6 dose levels: 75 mg Q2W, 140 mgQ2W, 300 mg Q4W，420mg Q4W, 450 mg Q6W，and 600 mg Q6W. Total duration of the study per subject is 12 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
-
Subjects must meet all of the following inclusion criteria in order to be included in the study:
- Provide a signed and dated informed consent form;
- Men or women with an age of 18 to 70 years of age at screening (Inclusive);
- BMI between18kg/m2 and 30kg/m2(Inclusive);
- Diagnosis of hyperlipidemia, and taking statins with moderate doses or above for at least 4 weeks;
- Fasting LDL-C between 100 mg / dl (2.6 mmol / L) and 220 mg / dl (5.7 mmol / L) at screening (Inclusive);
- Fasting triglycerides ≤ 400 mg (4.5 mmol / L) at screening.
-
Subjects who do not meet any of the following exclusion criteria cannot be included in the study:
-
Subject's current statin treatment are stable less than 4 weeks prior to random enrollment
-
New York Heart Association (NYHA) III or IV heart failure, or last left ventricular ejection fraction <30%
-
Uncontrolled hypertension, defined as repeated measurements confirmed, sitting systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg.
-
Diabetic patients have one of the following conditions;
- Known microvascular and macrovascular complications
- HbA1c>7.5% within 4 weeks before screening
-
Moderate or severe renal insufficiency, defined as the estimated glomerular filtration rate <60 ml / min / 1.73 m2 during screening (calculated using the MDRD formula)
-
Active liver disease or impaired liver function, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the normal upper limit (ULN) at screening.
-
Have previously undergone liver transplant surgery.
-
Creatine kinase (CK) ≥ 3 times the upper limit of normal (ULN) at screening.
-
At the discretion of the investigator, there are known active infections or major blood, kidney, metabolism, gastrointestinal or endocrine dysfunction.
-
Female subject of childbearing potential not willing to use an acceptable method(s) of effective birth control during treatment with investigational product and for an additional 15 weeks after the end of treatment with investigational product. Male subjects are reluctant to inform their female sexual partners about their participation in the clinical study.
-
Female subject is pregnant or breast feeding, planning to become pregnant or planning to breastfeed during treatment with investigational product and/or within 15 weeks after the end of treatment with investigational product..
-
Subjects have been treated with PCSK9 inhibitors or have participated in other PCSK-9 inhibitor studies
-
Subject has known sensitivity to the study drug and its excipients
-
Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment (for example, alcohol or other substance abuse, unable or unwilling to comply with the agreement or mental illness).
-
Currently receiving treatment in another investigational device or drug study, or less than 30 days before randomization since ending treatment on another investigational device or drug study(s) while participating in this study
-
In the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
-
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description IBI306 IBI306 Participants received one of 6 dose levels of IBI306 administered as multiple subcutaneous dose placebo placebo Participants received matching placebo dose regimen by subcutaneous injection.
- Primary Outcome Measures
Name Time Method AEs/SAEs up to 12 weeks • Percentage of participants with adverse events and severity of adverse events from the first dose to the last visit
- Secondary Outcome Measures
Name Time Method Percent change in mean LDL-C levels at week 6 and 12 relative to baseline baseline, week 6 and 12 Percent change in mean ApoB levels at week 6 and 12 relative to baseline baseline, week 6 and 12 area under curve (AUC) up to 12 weeks volume of distribution (Vd) up to 12 weeks clearance (CL) up to 12 weeks Percent change in Lp(a) from baseline at 12 weeks baseline and week 12 Percent change in mean Lp(a) levels at week 6 and 12 relative to baseline baseline, week 6 and 12 Tmax up to 12 weeks accumulation factor (AR) up to 12 weeks Percent change in ApoB/ApoA1 ratio from baseline at 12 weeks baseline and week 12 Cmax up to 12 weeks NAb up to 12 weeks The occurrence of neutralizing antibody (NAb) in serum before and after administration
Changes in LDL-C levels from baseline at 12 weeks baseline and week 12 Percent change in ApoB from baseline at 12 weeks baseline and week 12 half-life (T1/2) up to 12 weeks changes in blood PCSK-9 concentrations at different time points before and after administration relative to baseline up to 12 weeks Percent change in non-HDL-C cholesterol levels from baseline at 12 weeks baseline and week 12 Percent of patients with a 15% or more decrease in LDL-C levels from baseline at 12 weeks baseline and week 12 ADA up to 12 weeks The occurrence of anti-IBI306 antibody (ADA) in serum before and after administration
Percent change in LDL-C from baseline at 12 weeks baseline and week 12
Trial Locations
- Locations (1)
Peking University First Hospital
🇨🇳Beijing, China